Fast Track Group FTRK 深 滬
已收盤 05-08 16:00:00 美东时间
0.3988
0.000
-0.03%
華盛通- 最 高0.40
- 今 開0.3851
- 成交量 2.25万股
- 最 低 0.34
- 昨 收 0.3989
- 總市值 8698.825
- 52周最高 9.69
- 市盈率 靜 --
- 換手率 103.26%
- 52周最低 0.2916
- 委 比 93.81%
- 總股本 2.18万
- 歷史最高 9.69
- 量 比 3.28
- 振 幅 15.04%
- 歷史最低 0.2916
- 每 手 1
- 風險率 1.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
Pyxis Oncology appoints Nelson Azoulay as Chief Business Officer. With over 15 years of experience in corporate strategy and biopharma transactions, Azoulay will lead corporate development and advance MICVO, the company's lead ADC targeting EDB+FN in solid tumors. MICVO is in Phase 1/2 trials for recurrent/metastatic head and neck cancer and has received FDA Fast Track Designation. Azoulay's expertise in ADCs and strategic transactions is expecte...
05-07 20:05
Armata Gains FDA Fast Track for AP-SA02 Therapy
The latest update is out from Armata Pharmaceuticals ( ($ARMP) ). On May 7, 202...
05-07 19:57
KALA BIO Announces Reverse Stock Split
KALA BIO, Inc. announced a 1-for-50 reverse stock split effective May 8, 2026, with common stock resuming trading on a split-adjusted basis on May 11, 2026. The move reduces outstanding shares from 929 million to approximately 18.6 million. The new CUSIP number is 483119301. Fractional shares will be paid in cash. KALA BIO, a clinical-stage biopharmaceutical company, is advancing AI-driven solutions for the biotech industry through its Researgenc...
05-07 13:00
Bio-Techne Q3 2026 Earnings Call: Complete Transcript
Bio-Techne (NASDAQ:TECH) released third-quarter financial results and hosted an...
05-06 22:07
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
NRx Pharmaceuticals has initiated its first commercial manufacturing order for a preservative-free ketamine product, anticipating approval under the Generic Drug User Fee Act in Summer 2026. The company has completed GMP audits and is prepared for pre-approval inspection. The blow-fill-seal manufacturing process enables high throughput, supporting significant market penetration and scalability. NRx's product is the first US-manufactured preservat...
05-05 11:00
香港投资推广署：全球Fast Track计划2026即日起接受报名
第九届全球 Fast Track 计划2026即日起接受报名，截止日期为9月25日。这项旗舰计划首次涵盖八大垂直领域，并新增线上市场先导计划及全面升级路演比赛，为全球创新科技企业打造展示其解决方案的平台，并提供更多元、更灵活的途径，以香港为起点拓展亚洲及国际市场。
05-04 20:13
Cocrystal Pharma Features Mechanism Of Action And Clinical Advancement Of Oral Protease Inhibitor CDI-988 In Oral Presentation At 39th ICAR 2026
Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatmentFully enrolled first cohort is assessing the infectivity of
05-01 04:25
